Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer

September 30, 2020

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, clinical senior lecturer and a consultant medical oncologist at the University College-London Cancer Institute, discusses the importance of patient-reported outcomes (PROs) in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

PROs were completed for 66 of the 104 patients included in the GARNET study, says Kristeleit. The PROs indicated that dostarlimab (formerly TSR-042) was very well tolerated. In fact, 37% of patients reported improved scores, so the agent led to an improvement in quality of life (QoL) for some patients, Kristeleit says.

These PRO scores are very important, not only to understand and capture the effect of this drug on patients, but it is a factor acknowledged by regulators and licensing bodies as a very important component of licensing these drugs. Additionally, these PROs help promote understanding not just of the numerical or statistical findings that are being measured, such as response rate and duration of response, but also what that means for the patient taking the drug, explains Kristeleit. The drug was found to be very tolerable by patients; they have to take the agent for a long period of time and many experienced improved QoL while on dostarlimab, concludes Kristeleit.


x